J&J-related uncertainties are behind us now
11/03/25 -"Yesterday, J&J announced it would not exercise its option to license HexaBody-CD38 (previously deemed to be Darzalex’s successor) from Genmab, thereby ending the uncertainty around this ..."
Pages
51
Language
English
Published on
11/03/25
You may also be interested by these reports :
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...
12/06/25
Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap. The tide may have turned, strangely as part ...